glofitamab + polatuzumab vedotin

**glofitamab + polatuzumab vedotin** is a combination regimen used in the treatment of relapsed or refractory large B-cell lymphoma, particularly diffuse large B-cell lymphoma (DLBCL)[1][2][3].\n- **Glofitamab** is a bispecific monoclonal antibody that engages CD3 on T cells and CD20 on B cells, redirecting T cells to eliminate malignant B cells by cytotoxic immune response and cytokine release[1][2].\n- **Polatuzumab vedotin** is an antibody-drug conjugate targeting CD79b on B cells, delivering the cytotoxic payload monomethyl auristatin E (MMAE), a microtubule-disrupting agent that induces apoptosis in dividing B cells[4][6].\nThe combination takes advantage of non-overlapping mechanisms and toxicity profiles. Glofitamab-driven cytokine release syndrome is typically limited to cycle one, while polatuzumab vedotin’s main toxicity is cumulative neurotoxicity and cytopenias[1][2]. Both agents are administered intravenously.

Other names

glofitpolaGlofitamab + Polatuzumab VedotinColumvi + Polivy